Similar articles

Abstract: Objective: Mutations in LIM domain binding 3 (LDB3) gene cause idiopathic dilated cardiomyopathy (IDCM), a structural heart disease with a complicated genetic background. However, the association of polymorphisms in the LDB3 gene with susceptibility to IDCM in Chinese populations remains unexplored as dose the impact on clinical presentation. Methods: We sequenced all exons and the adjacent part of introns of the LDB3 gene in 159 Chinese Han IDCM patients and 247 healthy controls. Then we detected the distribution of polymorphisms in the LDB3 gene in all participants and assessed their associations with risk of IDCM. Additionally, we conducted a stratified genotype–phenotype correlation analysis. Results: The A allele of rs4468255 was significantly associated with IDCM (P<0.01). The rs4468255, rs11812601, rs56165849, and rs3740346 were also associated with diastolic blood pressure (DBP) and left ventricular ejection fraction (LVEF) (P<0.05). Notably, a higher frequency of rs4468255 polymorphism was observed in implantable cardioverter defibrillator (ICD) recipients under a recessive model (P<0.01), whereas the significant association disappeared after adjusting for potential confounders. However, in the dominant model, notable correlations could only be observed after adjusting for multi parameters. Conclusions: The rs4468255 was significantly correlated with IDCM of Chinese Han population. A allele of rs4468255 is higher in IDCM patients with ICD implantation, suggesting the influence of genetic background in the generation of this response. In addition, rs11812601, rs56165849, and rs3740346 in LDB3 show association with brain natriuretic peptide, DBP, and LVEF levels in patients with IDCM but did not show any association with IDCM susceptibility.

中国汉族特发性扩张型心肌病患者LDB3基因多态性与临床表现及植入型心律转复除颤器(ICD)植入的相关性研究

[1]Bänsch D, Antz M, Boczor S, et al., 2002. Primary prevention of sudden cardiac death in idiopathic dilated cardiomyopathy: the cardiomyopathy trial (CAT). Circulation, 105(12):1453-1458.

[2]Bondue A, Arbustini E, Bianco A, et al., 2018. Complex roads from genotype to phenotype in dilated cardiomyopathy: scientific update from the Working Group of Myocardial function of the European Society of Cardiology. Cardiovasc Res, 114(10):1287-1303.

[3]Faulkner G, Pallavicini A, Formentin E, et al., 1999. ZASP: a new Z-band alternatively spliced PDZ-motif protein. J Cell Biol, 146(2):465-475.

[4]Garfinkel AC, Seidman JG, Seidman CE, 2018. Genetic pathogenesis of hypertrophic and dilated cardiomyopathy. Heart Fail Clin, 14(2):139-146.

[5]Glöcklhofer CR, Steinfurt J, Franke G, et al., 2018. A novel LMNA nonsense mutation causes two distinct phenotypes of cardiomyopathy with high risk of sudden cardiac death in a large five-generation family. EP Europace, 20(12):2003-2013.

[6]Halliday BP, Cleland JGF, Goldberger JJ, et al., 2017. Personalizing risk stratification for sudden death in dilated cardiomyopathy: the past, present, and future. Circulation, 136(2):215-231.

[7]Hershberger RE, Hedges DJ, Morales A, 2013. Dilated cardiomyopathy: the complexity of a diverse genetic architecture. Nat Rev Cardiol, 10(9):531-547.

[8]Japp AG, Gulati A, Cook SA, et al., 2016. The diagnosis and evaluation of dilated cardiomyopathy. J Am Coll Cardiol, 67(25):2996-3010.

[9]Jiang ZH, Wang HY, Michal JJ, et al., 2016. Genome wide sampling sequencing for SNP genotyping: methods, challenges and future development. Int J Biol Sci, 12(1):100-108.

[10]Kadish A, Dyer A, Daubert JP, et al., 2004. Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. N Engl J Med, 350(21):2151-2158.

[11]Køber L, Thune JJ, Nielsen JC, et al., 2016. Defibrillator implantation in patients with nonischemic systolic heart failure. N Engl J Med, 375(13):1221-1230.

[12]Lang RM, Badano LP, Mor-Avi V, et al., 2015. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging, 16(3):233-270.

[13]Levitas A, Konstantino Y, Muhammad E, et al., 2016. D117N in Cypher/ZASP may not be a causative mutation for dilated cardiomyopathy and ventricular arrhythmias. Eur J Hum Genet, 24(5):666-671.

[14]Li ZH, Ai T, Samani K, et al., 2010. A ZASP missense mutation, S196L, leads to cytoskeletal and electrical abnormalities in a mouse model of cardiomyopathy. Circ Arrhythm Electrophysiol, 3(6):646-656.

[15]Lin CS, Guo XG, Lange S, et al., 2013. Cypher/ZASP is a novel A-kinase anchoring protein. J Biol Chem, 288(41):29403-29413.

[16]Losurdo P, Stolfo D, Merlo M, et al., 2016. Early arrhythmic events in idiopathic dilated cardiomyopathy. JACC Clin Electrophysiol, 2(5):535-543.

[17]Priori SG, Blomström-Lundqvist C, Mazzanti A, et al., 2015. 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: the task force for the management of patients with ventricular arrhythmias and the prevention of Sudden cardiac death of the European Society of Cardiology (ESC). Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC). Eur Heart J, 36(41):2793-2867.

[18]Reibis R, Salzwedel A, Bonaventura K, et al., 2017. Improvement of left ventricular ejection fraction in revascularized postmyocardial patients: indication for statistical fallacy. BMC Res Notes, 10:244.

[19]Sheikh F, Bang ML, Lange S, et al., 2007. “Z”eroing in on the role of Cypher in striated muscle function, signaling, and human disease. Trends Cardiovasc Med, 17(8):258-262.

[20]Strickberger SA, Hummel JD, Bartlett TG, et al., 2003. Amiodarone versus implantable cardioverter-defibrillator: randomized trial in patients with nonischemic dilated cardiomyopathy and asymptomatic nonsustained ventricular tachycardia—AMIOVIRT. J Am Coll Cardiol, 41(10):1707-1712.

[21]Tamburro P, Wilber D, 1992. Sudden death in idiopathic dilated cardiomyopathy. Am Heart J, 124(4):1035-1045.

[22]Towbin JA, Bowles NE, 2002. The failing heart. Nature, 415(6868):227-233.

[23]van der Zwaag PA, van Rijsingen IAW, de Ruiter R, et al., 2013. Recurrent and founder mutations in the Netherlands— phospholamban p.Arg14del mutation causes arrhythmogenic cardiomyopathy. Neth Heart J, 21(6):286-293.

[24]Vatta M, Mohapatra B, Jimenez S, et al., 2003. Mutations in Cypher/ZASP in patients with dilated cardiomyopathy and left ventricular non-compaction. J Am Coll Cardiol, 42(11):2014-2027.

[25]Weintraub RG, Semsarian C, Macdonald P, 2017. Dilated cardiomyopathy. Lancet, 390(10092):400-414.

[26]Wolff G, Lin YF, Karathanos A, et al., 2017. Implantable cardioverter/defibrillators for primary prevention in dilated cardiomyopathy post-DANISH: an updated meta-analysis and systematic review of randomized controlled trials. Clin Res Cardiol, 106(7):501-513.

[27]Yu HJ, Yuan C, Westenbroek RE, et al., 2018. The AKAP Cypher/Zasp contributes to β-adrenergic/PKA stimulation of cardiac Ca_V1.2 calcium channels. J Gen Physiol, 150(6):883-889.

[28]Zheng M, Cheng HQ, Li XD, et al., 2009. Cardiac-specific ablation of Cypher leads to a severe form of dilated cardiomyopathy with premature death. Hum Mol Genet, 18(4):701-713.

[29]Zheng M, Cheng HQ, Banerjee I, et al., 2010. ALP/Enigma PDZ–LIM domain proteins in the heart. J Mol Cell Biol, 2(2):96-102.

[30]List of electronic supplementary materials

[31]Table S1 Primer sequences of LDB3 gene used in polymerase chain reaction

[32]Table S2 Hardy-Weinberg equilibrium (HWE) testing among cases and controls